Hims & Hers Acquires Eucalyptus to Enter Australia, Canada, and Japan in First Major International Telehealth Expansion

The Quick Take

• Hims & Hers Health (HIMS) is expanding its global footprint by acquiring Eucalyptus, a telehealth operator with operations in Australia, Canada, and Japan
• The deal adds three strategic international markets to HIMS's primarily US-based telehealth platform, accelerating the company's global reach
• Eucalyptus specializes in digital health services including weight management and hormonal health, aligning with HIMS's core product categories

Hims & Hers Health is acquiring Eucalyptus, an Australian-founded digital health platform with operating presence in Australia, Canada, and Japan, marking the first significant international expansion for the US-listed telehealth company. The acquisition adds three geographies where Eucalyptus has established patient bases, digital health infrastructure, and regulatory approvals for prescription-based services including GLP-1 weight management medications and hormonal health treatments — categories that align directly with HIMS's core US product portfolio. The deal reflects HIMS's strategy to leverage its telehealth technology platform and brand across geographies where the regulatory pathway for online prescribing has already been established.

The Eucalyptus acquisition carries meaningful strategic and financial implications: international revenue diversification reduces HIMS's dependence on the highly competitive US telehealth market, where Amazon Clinic, Teladoc, and other platforms compete aggressively for the same consumer health demographics. Australia and Canada are mature digital health markets with established out-of-pocket private healthcare spending cultures that support subscription-based telehealth models similar to HIMS's US approach. Japan represents a longer-dated opportunity given its regulatory complexity for digital health services but offers an eventually large market for the demographic served by HIMS's core products.

Watch for HIMS's acquisition price disclosure and integration timeline announcement, which will determine the EPS dilution impact in the near term and the revenue synergy timeline. The regulatory approval timeline in Australia's TGA, Canada's Health Canada, and Japan's PMDA for any expanded prescribing activity post-acquisition is a secondary watch point. The macro variable for HIMS's international expansion is the GLP-1 prescribing regulatory environment in each market: if Ozempic and Wegovy become accessible via telehealth channels in Australia and Canada, HIMS's Eucalyptus vehicle becomes a significant channel for compounded GLP-1 distribution in markets where it currently lacks infrastructure.

Synthesized from 3 sources.